{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T02:42:11Z","timestamp":1782960131745,"version":"3.54.5"},"reference-count":23,"publisher":"American Society for Microbiology","issue":"2","license":[{"start":{"date-parts":[[2016,2,1]],"date-time":"2016-02-01T00:00:00Z","timestamp":1454284800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Antimicrob Agents Chemother"],"published-print":{"date-parts":[[2016,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Fungal nail infection (onychomycosis) is a prevalent disease in many areas of the world, with a high incidence approaching 23%. Available antifungals to treat the disease suffer from a number of disadvantages, necessitating the discovery of new efficacious and safe antifungals. Here, we evaluate the\n            <jats:italic>in vitro<\/jats:italic>\n            antifungal activity and nail penetration ability of ME1111, a novel antifungal agent, along with comparator drugs, including ciclopirox, amorolfine, terbinafine, and itraconazole. ME1111 showed potent antifungal activity against\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Trichophyton rubrum<\/jats:named-content>\n            and\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Trichophyton mentagrophytes<\/jats:named-content>\n            (the major etiologic agents of onychomycosis) strains isolated in Japan and reference fungal strains with an MIC range of 0.12 to 0.5 mg\/liter and an MIC\n            <jats:sub>50<\/jats:sub>\n            and MIC\n            <jats:sub>90<\/jats:sub>\n            of 0.5 mg\/liter for both. Importantly, none of the tested isolates showed an elevated ME1111 MIC. Moreover, the antifungal activity of ME1111 was minimally affected by 5% wool keratin powder in comparison to the other antifungals tested. The ME1111 solution was able to penetrate human nails and inhibit fungal growth in a dose-dependent manner according to the TurChub assay. In contrast, 8% ciclopirox and 5% amorolfine nail lacquers showed no activity under the same conditions. ME1111 demonstrated approximately 60-fold-greater selectivity in inhibition of\n            <jats:named-content xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" content-type=\"genus-species\" xlink:type=\"simple\">Trichophyto<\/jats:named-content>\n            n spp. than of human cell lines. Our findings demonstrate that ME1111 possesses potent antidermatophyte activity, maintains this activity in the presence of keratin, and possesses excellent human nail permeability. These results suggest that ME1111 is a promising topical medication for the treatment of onychomycosis and therefore warrants further clinical evaluation.\n          <\/jats:p>","DOI":"10.1128\/aac.01739-15","type":"journal-article","created":{"date-parts":[[2015,12,8]],"date-time":"2015-12-08T15:05:43Z","timestamp":1449587143000},"page":"1035-1039","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":20,"title":["Characterization of Antifungal Activity and Nail Penetration of ME1111, a New Antifungal Agent for Topical Treatment of Onychomycosis"],"prefix":"10.1128","volume":"60","author":[{"given":"Yuji","family":"Tabata","sequence":"first","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Pharmaceutical Research Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Takei-Masuda","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Pharmaceutical Research Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natsuki","family":"Kubota","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Pharmaceutical Research Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sho","family":"Takahata","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Pharmaceutical Research Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Ohyama","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Pharmaceutical Research Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaori","family":"Kaneda","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Pharmaceutical Research Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maiko","family":"Iida","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Pharmaceutical Research Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazunori","family":"Maebashi","sequence":"additional","affiliation":[{"name":"Meiji Seika Pharma Co., Ltd., Pharmaceutical Research Center, Yokohama, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.107754"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1067\/mjd.2000.104794"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2133.1995.tb02741.x"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1004105"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1001\/archderm.1997.03890450124022"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1517\/13543784.16.2.157"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00111-14"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2012.10.013"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-013-0152-x"},{"key":"e_1_3_2_11_2","first-page":"1124","article-title":"The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis","volume":"13","author":"Toledo-Bahena ME","year":"2014","unstructured":"Toledo-Bahena ME, Bucko A, Ocampo-Candiani J, Herz-Ruelas ME, Jones TM, Jarratt MT, Pollak RA, Zane LT. 2014. The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis. J Drugs Dermatol 13:1124\u20131132.","journal-title":"J Drugs Dermatol"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.2042-7158.1997.tb06127.x"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0378-5173(01)00989-9"},{"key":"e_1_3_2_14_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother","author":"Takahata S","year":"2014","unstructured":"Takahata S, Tabata Y, Takei-Masuda N, Kubota N, Maebashi K. 2014. Mechanism of action of ME1111, a new antifungal agent for topical treatment of onychomycosis, abstr F-1585. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_15_2","volume-title":"Approved standard M38-A2","author":"Clinical and Laboratory Standards Institute","year":"2008","unstructured":"Clinical and Laboratory Standards Institute. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi, 2nd ed. Approved standard M38-A2. Clinical and Laboratory Standards Institute, Wayne, PA.","edition":"2"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.3314\/jjmm.34.207"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1211\/jpp.62.06.0009"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/0022-1759(94)90396-4"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00992-15"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1080\/13693780310001656803"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1468-3083.2011.04373.x"},{"key":"e_1_3_2_22_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother","author":"Hui X","year":"2014","unstructured":"Hui X, Maibach H. 2014. In vitro human nail plate penetration of a novel antifungal agent ME1111, abstr F-1588. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_23_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology","author":"Tabata Y","year":"2014","unstructured":"Tabata Y, Nomoto M, Chikada T, Kubota N, Takei-Masuda N, Takahata S, Maebashi K. 2014. In vitro and in vivo nail penetration of ME1111, a novel antifungal agent for topical treatment of onychomycosis, abstr F-1589. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."},{"key":"e_1_3_2_24_2","volume-title":"Abstr 54th Intersci Conf Antimicrob Agents Chemother","author":"Ago K","year":"2014","unstructured":"Ago K, Nomoto M, Chikada T, Uchida M, Tsuchiya T, Shibasaki S, Maebashi K, Hiratsuka K. 2014. Nonclinical safety assessment of ME1111, a novel antifungal agent for the topical treatment of onychomycosis, abstr F-1593. Abstr 54th Intersci Conf Antimicrob Agents Chemother. American Society for Microbiology, Washington, DC."}],"container-title":["Antimicrobial Agents and Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01739-15","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/AAC.01739-15","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,21]],"date-time":"2022-02-21T20:28:19Z","timestamp":1645475299000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/AAC.01739-15"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2]]},"references-count":23,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2016,2]]}},"alternative-id":["10.1128\/AAC.01739-15"],"URL":"https:\/\/doi.org\/10.1128\/aac.01739-15","relation":{},"ISSN":["0066-4804","1098-6596"],"issn-type":[{"value":"0066-4804","type":"print"},{"value":"1098-6596","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2]]},"assertion":[{"value":"2015-07-27","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-01-29","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}